GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...
GlobalData on MSN8h
GSK reports positive findings from Phase III RSV vaccine trialThe vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...
Malay Mail on MSN6d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaGlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...
Emmetrope Ophthalmics, LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today ...
The injection provides protection for approximately ... Eligible patients should take whatever vaccine is available. How they work: GSK's Arexvy and Pfizer's Abrysvo introduce inactivated RSV protein ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback